ZyVersa Therapeutics Inc.

AI Score

0

Unlock

1.50
0.17 (12.78%)
At close: Jan 14, 2025, 3:59 PM
1.45
-3.33%
Pre-market Jan 15, 2025, 04:19 AM EST
undefined%
Bid 1.44
Market Cap 3.76M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 491.97
PE Ratio (ttm) 0
Forward PE n/a
Analyst Strong Buy
Ask 1.68
Volume 704,135
Avg. Volume (20D) 1,982,714
Open 1.31
Previous Close 1.33
Day's Range 1.31 - 1.60
52-Week Range 0.98 - 25.00
Beta undefined

About ZVSA

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, In...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 11, 2022
Employees 7
Stock Exchange NASDAQ
Ticker Symbol ZVSA

Analyst Forecast

According to 1 analyst ratings, the average rating for ZVSA stock is "Strong Buy." The 12-month stock price forecast is $240, which is an increase of 15900.00% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 months ago · Source
+39.56%
ZyVersa Therapeutics shares are trading higher aft... Unlock content with Pro Subscription
8 months ago · Source
+15.63%
ZyVersa Therapeutics shares are trading higher after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with IC 100 to potentially attenuate cardiac comorbidities in patients with Alzheimer's Disease.